Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine

AIM: In cancer immunotherapy, biomarkers are important for identification of responsive patients. This study was aimed to find biomarkers that predict clinical outcome of WT1 peptide vaccination. MATERIALS & METHODS: Candidate genes that were expressed differentially between long- and short-term...

Descripción completa

Detalles Bibliográficos
Autores principales: Takashima, Satoshi, Oka, Yoshihiro, Fujiki, Fumihiro, Morimoto, Soyoko, Nakajima, Hiroko, Nakae, Yoshiki, Nakata, Jun, Nishida, Sumiyuki, Hosen, Naoki, Tatsumi, Naoya, Mizuguchi, Kenji, Hashimoto, Naoya, Oji, Yusuke, Tsuboi, Akihiro, Kumanogoh, Atsushi, Sugiyama, Haruo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Science Ltd 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241910/
https://www.ncbi.nlm.nih.gov/pubmed/28116121
http://dx.doi.org/10.4155/fsoa-2015-0008
Descripción
Sumario:AIM: In cancer immunotherapy, biomarkers are important for identification of responsive patients. This study was aimed to find biomarkers that predict clinical outcome of WT1 peptide vaccination. MATERIALS & METHODS: Candidate genes that were expressed differentially between long- and short-term survivors were identified by cDNA microarray analysis of peripheral blood mononuclear cells that were extracted from 30 glioblastoma patients (discovery set) prior to vaccination and validated by quantitative RT-PCR using discovery set and different 23 patients (validation set). RESULTS: SDC-4 mRNA expression levels distinguished between the long- and short-term survivors: 1-year survival rates were 64.0 and 18.5% in SDC4-low and -high patients, respectively. CONCLUSION: SDC-4 is a novel predictive biomarker for the efficacy of WT1 peptide vaccine.

Ejemplares similares